Research programme: gonadotrophin releasing hormone antagonists - Agouron/Alanex

Drug Profile

Research programme: gonadotrophin releasing hormone antagonists - Agouron/Alanex

Alternative Names: Gonadotrophin releasing hormone antagonists research programme - Alanex

Latest Information Update: 23 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alanex Corporation
  • Class
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Endometriosis

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 24 May 1999 Agouron acquired by Warner-Lambert
  • 21 Oct 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top